Notre site utilise des cookies. Cela nous permet d'optimiser votre expérience utilisateur.
En poursuivant votre navigation sur ce site, vous acceptez l'utilisation de cookies. Vous trouverez de plus
amples informations dans notre
déclaration de confidentialité.
In this year's Swiss Biotech Report, the Swiss stock exchange looks back on the past 20 years of successful biotech listings.
Switzerland's biotech sector is a growing and competitive industry. The
Swiss Biotech Report 2018[pdf] provides an outlook on key
biotech trends as well as a look back on the challenges the sector has successfully overcome in the past. This is illustrated
by articles ranging from research and product development to supporters, funding and market launch. The report also delivers
key performance figures for the Swiss biotech industry. The new report was presented at this year's
Swiss Biotech Day, the leading Swiss biotechnology conference.
IPOs are an intriguing option for biotech firms to raise capital, as the number of successful listings on SIX Swiss Exchange
AG over the past two decades shows. The biotech companies represent an aggregated market capitalization of some CHF 25 billion
(as at the end of 2017). Christian Fehr, Relationship Manager Primary Markets SIX Swiss Exchange AG, offers an overview of
the listings and insight into how the Swiss stock exchange actively supports the companies following their IPO.
Europe's leading exchange for Life Sciences
SIX Swiss Exchange AG is Europe's leading exchange
for Life Sciences companies, representing around 40% of the European Life Sciences
market capitalization. SIX Swiss Exchange AG offers both Swiss and foreign companies an ideal environment for raising
capital. To learn more about our advantages for equity issuers, you can watch our
film or read our